50AM Factory direct sale.. 99% pure, high quality, fast and safe delivery,White freeze-dried powder
TDS 2 Inquiries
1334953-95-5
Pharmaceutical
99%
SHENZHENG
KSD
10vials
2026-11-17
Semaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
MTP 131 acetate
CAS No.:1334953-95-5
Categories:
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Semaglutide
-
Location:
Licheng District, Jinan City, Shandong Province
-
Payment Terms:
100% TT in advance
-
Average lead Time:
14
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
Certifications:
Retatrutide coa
">KSD -
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
United States
Elamipretide Acetate CAS 1334953-95-5
10 G May 19, 2026
United States
ss-31
10 G May 19, 2026 Post an enquiry for this product

KSD